Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.

NEW YORK, July 6 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq:
DCTH), a medical technology company testing its proprietary treatment method
for primary and metastatic cancers to the liver, announced today that Eamonn
P. Hobbs, 51, a member of the Delcath Board of Directors since October 2008,
has been appointed President and CEO of the Company. Mr. Hobbs succeeds
Richard Taney who has led the company since December 2006 and will continue to
serve on the Company's Board of Directors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Mr. Hobbs has over 25 years of experience in the interventional radiology,
interventional cardiology and gastroenterology medical device industries.
From 1988 until earlier this year, Mr. Hobbs was President and CEO of
AngioDynamics, Inc. (Nasdaq: ANGO). As a co-founder, he built AngioDynamics
into a leading medical technology company with an international market
presence and a highly diverse product line. Throughout his tenure at
AngioDynamics, Mr. Hobbs led the Company's efforts in marketing, strategic
planning, product development, and general management. In 2004, AngioDynamics
was spun off from E-Z-EM, Inc., a healthcare company focused on diagnostic
technologies, where Mr. Hobbs served as Senior Vice-President since 1988.

Before his involvement with these companies, Mr. Hobbs was the Director of
Marketing and Product Development at NAMIC, Founder, President and CEO of
Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated.
He received a Bachelor of Science in Plastics Engineering with a Biomaterials
emphasis at the University of Massachusetts in 1980. In addition, Mr. Hobbs
was elected to and currently serves on the Board of Directors of the Society
of Interventional Radiology Foundation and as Vice Chairman of the Medical
Device Manufacturers Association.

Commenting on his new position at Delcath, Mr. Hobbs stated, "I am delighted
to be leading Delcath during this exciting time in our development. Richard
has done an exceptional job leading the Company over the past two-plus years
and I look forward to building on recent achievements. The promise of our
drug delivery platform and its unique position in the interventional oncology
space offers the opportunity to address a large and growing unmet medical
need. I look forward to completing our Phase III clinical trials and
submitting for FDA approval in a timely manner. At the same time, we will
focus on expanding our presence and relationships within the medical community
and look forward to delivering this exciting treatment modality to oncology
patients worldwide."

"Eamonn is a proven leader with extensive experience in all aspects of medical
device commercialization and the entire Board feels that he is the best person
to lead our Company through the next phase of our development," added Dr.
Harold Koplewicz, Chairman of Delcath's Board of Directors.

Commenting on this transition, Mr. Taney stated, "The Delcath management team
and our Board of Directors are very proud of the tremendous progress our
Company has made over the past two and a half years. As we approach
completion of our pivotal Phase III trial, we are increasingly shifting our
focus towards the commercialization of our technology. I look forward to
working with Eamonn during this transition and to my continued involvement as
a committed member of our Board of Directors."

About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical device company specializing in cancer
treatment. The Company is testing a proprietary, patented drug delivery
system for the treatment of liver cancers. Delcath's novel drug delivery
platform is testing the delivery of ultra-high doses of anti-cancer drugs to
the liver while preventing these high doses of drug from entering the
patient's bloodstream. The Company is currently enrolling patients in Phase
III and Phase II clinical studies for the treatment of liver cancers using
high doses of melphalan. The Company's intellectual property portfolio
consists of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the Company's
website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor
for forward-looking statements made by the Company or on its behalf. This news
release contains forward-looking statements, which are subject to certain
risks and uncertainties that can cause actual results to differ materially
from those described. Factors that may cause such differences include, but are
not limited to, uncertainties relating to our ability to successfully complete
Phase III clinical trials and secure regulatory approval of our current or
future drug-delivery system and uncertainties regarding our ability to obtain
financial and other resources for any research, development and
commercialization activities. These factors, and others, are discussed from
time to time in our filings with the Securities and Exchange Commission. You
should not place undue reliance on these forward-looking statements, which
speak only as of the date they are made. We undertake no obligation to
publicly update or revise these forward-looking statements to reflect events
or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.

Investor, Steve DiMattia, Managing Director of EVC Group, Inc.,
+1-646-201-5445, sdimattia@evcgroup.com, or Media, Robin Wagge, Senior Vice
President of Rubenstein Associates, for Delcath Systems, Inc.,
+1-212-843-8006, rwagge@rubenstein.com